WO2004100923A1 - Composition a usage externe administree par voie percutanee - Google Patents

Composition a usage externe administree par voie percutanee Download PDF

Info

Publication number
WO2004100923A1
WO2004100923A1 PCT/CN2003/000358 CN0300358W WO2004100923A1 WO 2004100923 A1 WO2004100923 A1 WO 2004100923A1 CN 0300358 W CN0300358 W CN 0300358W WO 2004100923 A1 WO2004100923 A1 WO 2004100923A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
composition
skin
acne
carotene
Prior art date
Application number
PCT/CN2003/000358
Other languages
English (en)
French (fr)
Inventor
Busang Liu
Tongho Lin
Original Assignee
Lotus Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lotus Pharmaceutical Co., Ltd. filed Critical Lotus Pharmaceutical Co., Ltd.
Priority to KR1020057021808A priority Critical patent/KR100673044B1/ko
Priority to BRPI0318343-2A priority patent/BR0318343A/pt
Priority to EP03727132A priority patent/EP1625844A4/en
Priority to CA002525465A priority patent/CA2525465A1/en
Priority to PCT/CN2003/000358 priority patent/WO2004100923A1/zh
Priority to JP2004571754A priority patent/JP2006525945A/ja
Priority to AU2003234980A priority patent/AU2003234980B2/en
Priority to US10/811,420 priority patent/US7655255B2/en
Publication of WO2004100923A1 publication Critical patent/WO2004100923A1/zh
Priority to US11/446,051 priority patent/US20060222689A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/678Tocopherol, i.e. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/008Preparations for oily skin

Definitions

  • the present invention relates to a topical composition for transdermal administration, which can maintain and improve the skin. . technical background
  • the human skin structure includes the epidermis, dermis, subcutaneous adipose tissue, sebaceous glands, sweat glands, hair, and finger cuffs.
  • the thick layer under the epidermis is called the dermis, and the hair is surrounded by the surrounding hair crusts, and sebaceous glands are attached to the sides.
  • the sebaceous glands can secrete sebum.
  • the sebum penetrates the surface of the skin through the hair and hair loops, and then becomes a thin film of fat, which attaches to the surface of the skin and protects the skin.
  • the amount of sebaceous glands affects the type of skin, and is usually divided into oily skin, dry skin and mixed skin.
  • Acne is generally considered to be acne, adolescent gangrene, a chronic inflammation of the hairy pimples, the sebaceous glands.
  • Acne usually appears on the forehead, around the nose, around the cheeks, and even on the back, chest, thighs, and other hairy places. It can be divided into acne type, inflammation type, and cyst type according to the symptoms.
  • puberty when the gonads begin to mature, the testicles, ovaries, and adrenal glands increase in male hormones, which stimulates the sebaceous glands of the human skin, enlarges them, secretes a large amount of sebum, accumulates in the sebaceous glands and hair follicles, and becomes inflamed by bacteria.
  • Blackheads or whiteheads usually form first. Acne is then infected with bacteria to form pimples, pustules, nodules, and bloating, which are acne. When male hormones are secreted too much, red, itchy, hot, hot, and peeling skin may appear on the T-shaped part of the face and the skin under the eyelids, and sometimes microvessels may even appear obviously, which is called apolipic dermatitis.
  • sodium chloride can be the main body to maintain the osmotic pressure of body fluids, especially 0.9% solution is called physiological saline, but high-concentration sodium chloride solution cannot be absorbed from the skin, but stimulates the skin mucosa and causes dehydration;
  • external preparations can stimulate the skin or sterilize, it is difficult to produce a moisturizing effect that prevents skin moisture from evaporating.
  • glucose can increase the quality of sugar and increase the function of whole body cells, it is a nutrient that enhances the metabolic function of organisms. It also has a detoxifying effect. Even if glucose is added to a topical preparation, it is difficult to achieve the above-mentioned special effects exhibited by glucose.
  • Various therapeutic agents and cosmetic agents have been used to treat various skin symptoms, for example, hydrocortisone for itching and erythema in atopic dermatitis, sulconazole nitrate for skin fungal infections, Tretinoin for photo-aging and 5-fluorouracil for psoriasis and skin cancer.
  • Penetration enhancers are commonly added to dermatological treatment drugs, such as difluorenylsulfoxide (DMSO), difluorenylfluoramide, fluorenyldecylsulfoxide (US Patent No. 3,527,864), difluorenylacetamide (US Patent No. 3,472,931), and N-alkyl-2-pyrrolidone (US Patent No.
  • the above-mentioned penetration enhancers have some disadvantages, for example, disulfoxide has a bad smell and body odor, causing skin burns and erythema, reducing the transparency of the crystalline skin, and even causing animal tissue necrosis (Martindale, The Extra Pharmacopoeia, pages 1461-1463, Twenty-Seventh Edition, 1977). Dimethylformamide and dimethylacetamide can also cause skin burning and erythema.
  • U.S. Patent No. 5,030,451 by Trebosc et al. Discloses a cosmetic composition containing an improved caffeine derivative as an active agent, and claims that the disclosed formula has "good and long-lasting fat-decomposing properties, thus demonstrating weight loss and treatment of sebum Granular is very effective.
  • Mausner U.S. Patent No. 5,215,759 provides the use of methylsilanol theophyllin acetate alginate and methylsilanol mannuronate as anti-cellulite ingredient.
  • U.S. Patent No. Kligman Topical application of retinoid No. 5,051,449 can improve fat granules to a limited extent. Kligman claims to include skin thickening, increased neovascularization, and moderate to significant improvement observed with pinch test.
  • Vitamin A Acid is also called Tretinoin, Retinoids. Its structure belongs to the derivative of Vitamin A. Its main function is to remove the cutin, because it can remove the uppermost layer of the cuticle of the epidermis. Keratin removal can improve pore blockage, also improve skin wrinkles, circulating blood flow around the face, reduce pigmentation marks and block skin keratinization.
  • vitamin A products have side effects such as photosensitivity to the skin and excessive use resulting in dryness, redness, fever, itching, and dermatitis.
  • the present invention proposes a composition for external use for transdermal administration without vitamin A acid.
  • the object of the present invention is to provide a topical composition for transdermal administration.
  • the composition can be used for skin maintenance and treatment to improve skin acne, acne, acne, and has no antioxidant effect of vitamin A acid. combination.
  • the invention provides a composition for external use for transdermal administration, the main components of which include vitamin C 1-45% W / W, vitamin B group 1 to 5% W / W, carotene 1 to 3% W / W, Vitamin E 2-90% w / w.
  • the present invention also provides a composition for external use for transdermal administration, the main components of which are vitamin C 4-15% W / W, vitamin B group 1 ⁇ 3% W / W, carotene 1 ⁇ 2% W / W, vitamins E 20-65% W / W; in the above-mentioned composition for external use, its composition also includes perfume 0.1 ⁇ 2% W / W, thickener 1 ⁇ 5% W / W, surfactant 1 ⁇ 8% W / W And the right amount of distilled water.
  • the above-mentioned external composition is applied to a localized position on the skin.
  • the invention also provides a topical composition for transdermal administration.
  • the composition is used to prepare a medicament for treating acne, acne, and acne. It can also be used for skin care and has an antioxidant effect.
  • the combination The main ingredients are vitamin C 1 ⁇ 45% W / W, vitamin B group
  • the external composition provided by the present invention is mainly composed of 1 to 45% W / W vitamins (1 to 5% W / W vitamin B group, 1 to 3% W / W carotene), 2 ⁇ 90% W / W vitamin E is composed of 0.1 ⁇ 2% W / W perfume, 1 ⁇ 5% W / W thickener, 1 ⁇ 8% W / W surfactant, and the remaining distilled water. The sum of the contents of each composition is 100%.
  • the external composition for transdermal administration provided by the present invention can prevent and treat skin acne, acne, and acne.
  • the composition provided by the present invention can maintain the skin, can also treat and improve skin acne, acne, acne, and has an antioxidant effect. Because it does not contain vitamin A acid, it does not make the skin light sensitive. While improving the skin symptoms, it can avoid side effects such as dry skin, redness, fever, itching, and dermatitis. Even if it is used for a long time, there is no excessive problem.
  • the present invention provides a topical composition for transdermal administration.
  • the composition is mainly composed of vitamin C, vitamin B group, carotene, vitamin E and flavor, thickener, surfactant, and can be used topically. It is used for skin care and is a pharmaceutical composition for treating acne, acne, acne and antioxidants.
  • FIG. 1 is a graph showing the difference in the amount of sebum produced after the external composition of the present invention is applied to the skin, where the abscissa is time (week), and the ordinate is the amount of sebum (g / cm 2 ).
  • the invention provides a composition for external use for transdermal administration, which is a composition that does not contain vitamin A acid and can maintain skin and treat and improve skin symptoms such as acne, acne, and acne.
  • the composition for external use of the present invention is mainly composed of vitamin C, vitamin B group, carotene, vitamin E, and flavor, thickener, and surfactant.
  • the composition of the composition is an essential vitamin for the human body, and the main component does not contain vitamin A acid, and there is no excessive problem even if it is used for a long time. Vitamins have a small amount in the body, but their functions are extremely important. The human body cannot synthesize itself and must rely on external intake.
  • vitamin C has the functions of preventing the production of lipid peroxides, promoting the formation of collagen, assisting various enzymes, delaying the aging of cells, and promoting blood circulation and reducing melanin gradually; therefore it is generally believed to help the skin Regenerates, suppresses melanin production and enhances immunity.
  • Vitamin B complex is not single but several vitamins together, including vitamins
  • vitamin B 2 riboflavin
  • niacin vitamin B 5 (pantothenic acid), vitamin B 6 (pyridoxal), folic acid (folic acid), vitamin B 12 (cobalamin), and biotin (biotin)
  • other components mainly coenzyme components, function to promote glucose oxidation, fat and protein release energy to maintain the normal function of the nervous system, necessary for cell growth, regeneration, blood cell generation and synthesis of nuclear proteins and myelin, And can activate folate auxiliary enzymes and promote red blood cell production.
  • Vitamin E is considered to be an antioxidant, which can inhibit the aggregation of platelets, prevent the oxidation of red blood cell membranes to prevent them from being damaged and cause anemia, maintain the integrity of cell membranes in the tissue and promote the normal function of linoleic acid, and protect the structure and function of muscle and nerve tissue In order to increase the blood flow of the terminal blood vessels, the blood flow can be effectively improved.
  • vitamin E has the above-mentioned activities, currently listed products such as vitamin E with aloe wal green (Wal Green), or products containing vitamin E L'oreal Furtur E has no record of maintaining skin or treating acne, acne, pimples, and anti-oxidants.
  • composition of the present invention shows that the main component of the composition in the proportion has good efficacy. Therefore, it must be emphasized that although the composition of the present invention is composed of vitamins (3, vitamin B group, carotene, vitamin E and flavor, thickener, and surfactant), it is not inferred by conventional techniques in the technical field.
  • the main ingredients of the composition of the present invention are composed of vitamin C 1 to 45% W / W, vitamin B group 1 to 5% W / W, carotene 1 to 3% W / W, vitamin E 2 to 90% W / W and fragrance 0.1. ⁇ 2% W / W, thickener 1 ⁇ 5% W / W, surfactant 1 ⁇ 8% W / W, and appropriate amount of distilled water.
  • the main component ratio is preferably vitamin C 4 to 15% W / W, vitamin B group 1 to 3% W / W, carotene 1 to 2% W / W, and vitamin E 20 to 65% W / W.
  • the invention provides a vitamin A-acid-free composition, which is a composition that can be administered topically to treat acne, acne, and acne. Since the present invention is composed of vitamin C, vitamin B group, carotene, vitamin E and fragrance, thickener, and surfactant, it can be applied transdermally to the skin, facial area and other extremities to achieve skin maintenance. Treatment improves acne, acne, acne and other symptoms, as well as anti-oxidation of skin.
  • composition for topical administration may be added with various excipients, carriers or diluents as necessary to provide an ointment form, emulsion, lotion or patch directly applied to the affected area.
  • the dosage form is added with a binder such as starch and sodium carboxymethyl cellulose in a conventional formulation method in the art, or the pH value is adjusted to a proper level by using a phosphate buffer solution; the dosage form may also be added according to a conventional formulation method.
  • natural plant extracts such as licorice can also be used.
  • Distilled water 15 mixes raw vitamin C, vitamin B complex, dissolved in a small amount of distilled water, and also mixes carotene, vitamin E, flavor, surfactant, and thickener. Then, mix the two solutions and make up for the amount of distilled water.
  • Example 4
  • Distilled water qs Mix the above raw materials Vitamin C, Vitamin B complex-dissolved in a small amount of distilled water, and mix carotene, Vitamin E, Flavor, Surfactant, Thickener Then, mix the two solutions and make up for the amount of distilled water.
  • Example 6 Distilled water qs Mix the above raw materials Vitamin C, Vitamin B complex-dissolved in a small amount of distilled water, and mix carotene, Vitamin E, Flavor, Surfactant, Thickener Then, mix the two solutions and make up for the amount of distilled water.
  • Thickening agent 2 Distilled water q s Dissolve the above raw materials Vitamin C, Vitamin B complex-complex in a small amount of distilled water, Carotene, Vitamin E, Flavor, Surfactant ), The thickeners are mixed, and then the two solutions are mixed and the amount of distilled water is made up.
  • Vitamin E 30 Vitamin c 10 Vitamin B complex -complex 5 Carotene 2 Flavor 2 Surfactant 10 Thickening agent 5 Permeation enhancer 1.5 Distilled water qs
  • the patient has a pustule with oral antibiotics, such as tetracycline or doxycycline (Vibramycin) for one week, other acne treatments, such as vitamin A acid, orally or topically, or hormone therapy .
  • oral antibiotics such as tetracycline or doxycycline (Vibramycin)
  • other acne treatments such as vitamin A acid, orally or topically, or hormone therapy .
  • Lo-108 has the effect of treating acne, even exfoliating, reducing the amount of sebum secretion, sterilizing and anti-inflammatory, and increasing the moisture content of keratin.
  • Test 2 Controlled assessment of sebum spill-out inhibition
  • the test for sebum spillage is to measure the amount of oil on the skin surface using a sebometer 810 PC (Courage and Khazaka Ltd, Germany). Because of the difference in the percentage of sebum on the left and right sides, many interference variables can be minimized.
  • the principle of sebum measurement is to use a 0.1 mm thick, opaque plastic material with an area of 64 mm 2 in front of the device. After pressing it on the skin surface for 30 seconds, it increases the transparency due to the absorption of sebum, and increases linearly with the amount of sebum. Sebum is directly proportional to transparency, as shown in Table 2. Measurements via a photometer can be converted to mg / cm2 via the formula. Skin fat determination
  • test group and the control group are the skin on the left and right sides of the same person's forehead, interference factors such as changes in temperature and humidity, the degree of exercise of the subject, and the degree of sweating can be excluded.
  • Lo-108 can effectively remove or suppress oil and fat secretion for more than 12 hours, so that the amount of open sebum in the sebaceous glands (one of the main causes of acne) can be temporarily relieved. This effect can be achieved in a short period of time, and daily use can maintain its effect of suppressing sebum for more than four weeks.
  • treat * time is the interaction between treatment and time.
  • Rats used in this experiment were eight weeks old, and male rats (Wistar species;) were raised at Chenggong University Animal Center, which is the only animal breeding unit in the south that meets foreign requirements (SPF). Rats were housed in an air-conditioned animal room at 25 ⁇ 1 ° C. All rats were free to eat and drink.
  • This step mainly refers to the experimental method of Kistler et al., And uses the observation of animal control comparison.
  • the experimental steps are as follows: each rat is anesthetized with pentobarbital at 65 mg / kg, and after it is lethargic, the back is divided into four fixed areas, each of which is about 4 cm 2 ; The inner hair is shaved clean. Then, place red iron pieces (temperature around 80-85 ° C) on the four areas of the back for about 10 seconds, causing burns to the back of the rats. After the procedure is completed, remove the iron sheet and use hydrogen peroxide (37%) for simple disinfection and clean the wound.
  • This experiment uses three strains of Staphylococcus aureus,

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Description

经皮给药的外用组合物 技术领域
本发明涉及一种经皮给药的外用组合物,其可保养并改善皮肤,是具有 治疗痤疮 (acne)、 粉刺、 青春痘及抗氧化作用的不含维生素 A酸的局部使用 的药物组合物。 技术背景
人体皮肤构造包括有表皮、 真皮、 皮下脂肪组织、 皮脂腺、 汗腺、 毛 发及指曱, 表皮下面厚的一层, 称为真皮, 毛发被周围的毛嚢所包围, 其 侧面附有皮脂腺。 皮脂腺可分泌皮脂, 皮脂经由毛发和毛嚢, 渗透到皮肤 表面, 然后变成脂肪薄膜, 附着在皮肤表面, 有保护皮肤的功能。 皮脂腺 的多寡影响皮肤的类型, 通常分为油性皮肤、 干性皮肤与混合性皮肤。
痤疮通常认为是粉刺, 青春疽, 属于一种毛嚢、 皮脂腺的慢性炎症。 青春痘通常出现在额头、 鼻翼四周、 两颊, 甚至背部、 前胸、 大腿等全身 有毛嚢的地方, 可随其呈现症状不同区分为粉刺型、 发炎红肿型及囊肿型。 青春期男女当性腺开始成熟、 睾丸及卵巢、 肾上腺的雄性激素含量增高, 因而刺激人体皮肤的皮脂腺, 使其肥大, 分泌大量皮脂, 堆积于皮脂腺、 毛囊, 经细菌作用而发炎。 通常先形成黑头粉刺或白头粉刺, 粉刺再受到 细菌感染形成丘疹、 脓疱、 结节、 嚢肿等症候, 就是青春痘。 当男性荷尔 蒙分泌过多, 可能在面部 T字部位及眼皮下面的皮肤, 出现红、 痒、 热、 烫、 脱皮的现象, 有时候甚至还会明显出现微血管, 称为脂漏性皮炎。
为改善上述问题, 通常需要外用剂具有对皮肤的清洁、 杀菌作用, 防 止皮肤水份蒸发, 增进保湿作用等效果。 例如美国专利第 3,574,854号记载 关于含氯化钠成分可以柔软肌肤的乳霜, 德国专利公开第 3,327,840号说明 书披露含矿物质盐类使肌肤卫生洁净的申请。 美国专利第 3,859,436号记载 了混合葡萄糖可使肌肤润滑的糖类, 美国专利 3,777,597号公报记载了刮胡 须用葡萄糖水溶液。
其中氯化钠虽然可成为维持体液渗透压的主体, 尤其 0.9 %溶液被称为 生理盐水, 但高浓度氯化钠溶液无法从皮肤吸收, 反而刺激皮肤粘膜引起 脱水作用; 因此添加氯化钠的外用剂虽可刺激皮肤或杀菌, 但很难产生防 止皮肤水分蒸发的促进保湿作用。 葡萄糖虽然可提高糖分原质, 使全身细 胞机能亢进, 是增进生物体代谢机能的营养剂, 亦具有解毒作用, 但是除 非做为口服补给、 经由静脉注射或肌肉注射提供补给, 在直接敷布于皮肤 的外用剂中即使添加葡萄糖, 亦难以达到葡萄糖呈现的上述特有效果。
已有各种治疗剂及化妆剂用于处理多种皮肤症状, 例如, 针对异位性 皮肤炎中搔痒及红斑所用的氢化可的松, 皮肤霉菌感染用的硝酸硫康唑 ( sulconazole nitrate ), 光老化用的维 A酸( tretinoin ), 及治疗牛皮癣与皮 肤癌用的 5-氟脲嘧啶。 在皮肤病治疗药物中通常添加渗透促进剂, 例如二 曱亚砜 (DMSO)、 二曱基曱酰胺、 曱基癸基亚砜 (美国专利 (US Patent )第 3,527,864号)、 二曱基乙酰胺(美国专利第 3,472,931号), 及 N-烷基 -2-鎇 咯烷酮 (美国专利第 3,696,516号)。 但是, 上述渗透促进剂系分别产生一 些缺点, 例如, 二曱亚砜有异味及体臭, 造成皮肤灼伤及红斑, 减低水晶 体皮肤的透明性, 甚至于造成动物组织坏死 (Martindale , The Extra Pharmacopoeia, pages 1461-1463, Twenty-Seventh Edition, 1977 )。 二曱基 甲酰胺及二曱基乙酰胺亦可造成皮肤烧灼感及红斑。
另外, Trebosc等的美国专利第 5,030,451 号披露含改良咖啡因衍生物 作为活性剂的化妆用组成物, 称该公开的配方具有 "良好及长效的分解脂 肪的性质, 因而证明在瘦身及治疗皮脂粒方面非常有效"。 Mausner美国专 利第 5,215,759号提供了使用曱基硅烷醇茶碱乙酸盐海藻酸盐 (methylsilanol theophyllin acetate alginate)及曱基硅烷醇甘露糖醛酸盐(methylsilanol mannuronate)作为去脂肪 (anti-cellulite)的成分。 如 Kligman 的美国专利第 5,051,449 号的局部施用视黄醛 (retinoid), 能有限地改善脂肪粒, Kligman 称包括皮肤增厚, 新血管增加, 及使用捏挟测试可观察到中度至明显改善。
美国专利申请第 20020099094 号披露氨基左旋醣酸光力疗法 (aminolevulinic acid-photod namic therapy) Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris = 美国专利申请第 20020061855 号披露使用水、 乙二醇 (glycol)的治疗痤疮的组成物, 美国专 利 申请第 20010056071 号披露使用 resveratrol (3,4',5- trihydroxy -trans-stilbene), 褪黑激素 (melatonin)、 维生素 (vitamins) D、 E、 A的治疗痤 疮组成物。
另外, Shapiro SS 与 Saliou C. 在 2001年 Nutrition第 17卷第 10期第 839页至第 44页说明以维生素 、 维生素 D及其衍生物搭配维生素(、 维 生素 E、 辅酶 (coenzyme) Q之类抗氧化物可改善皮肤, 治疗痤疮。 维生素 A 酸 (Vitamin A Acid)又称为 Tretinoin, Retinoids, 其结构属于维生素 A的衍 生物, 主要作用为除去角质, 因为它能将表皮的角质层最上层的角质去除, 可以改善毛孔的阻塞, 也可以改善皮肤皱纹、 脸部周边循环血流、 减少色 素斑痕和阻断皮肤角化, 亦可促进上皮细胞更新和促进脱落, 抑制角质合 成, 防止面疱的形成。 但是多数维生素 A酸的产品存在着使肌肤产生光敏 感, 以及过度使用导致皮肤干燥、 红肿、 发热、 发痒、 皮炎等副作用。
由上述可知, 虽然有些专利具有治疗痤疮、 或是去脂肪、 治疗数种皮肤 症状的作用, 但是均具有缺点而对皮肤产生伤害。 由此, 本发明提出一种 不含维生素 A酸的经皮给药的外用组合物。 发明内容 本发明的目的在于提供了一种经皮给药的外用组合物, 该组合物是可 用于保养皮肤并治疗改善皮肤痤疮、 粉刺、 青春痘及具抗氧化作用的不含 维生素 A酸的组合物。 本发明提供了一种经皮给药的外用组合物, 其主要成分包括维生素 C 1-45% W/W、维生素 B群 1~5%W/W、胡萝卜素 1〜3%W/W、维生素 E 2-90% w/w。
本发明还提供一种经皮给药的外用组合物, 主要成分为维生素 C 4〜15% W/W、 维生素 B群 1~3%W/W、 胡萝卜素 1~2%W/W、 维生素 E 20-65% W/W; 上述的外用组合物中, 其组成还包括香料 0.1〜2% W/W、 增 稠剂 1〜5% W/W、 表面活性剂 1~8% W/W及适量蒸馏水。
上述的外用组合物应用于皮肤的局部位置。
本发明还提供了一种经皮给药的外用组合物, 该组合物用于制备对痤 疮、 粉刺、 青春痘具有治疗作用的药物, 还可用于保养皮肤, 并具有抗氧 化作用, 所述组合物主要成分为维生素 C 1~45%W/W、 维生素 B群
1〜5%W/W、 胡萝卜素 1〜3%W/W、 维生素 E 2~90%W/W与香料 0.1~2% W/W 增稠剂 1~5%W/W、 表面活性剂 1〜8%W/W以及适量蒸馏水。
本发明提供的外用组合物, 其主要成分是由 1 ~ 45%W/W的维生素(、 1 ~ 5%W/W的维生素 B群、 1 ~ 3%W/W的胡萝卜素 (carotene), 2 ~ 90%W/W 的维生素 E与 0.1 ~ 2%W/W的香料、 1 ~ 5%W/W的增稠剂、 1 ~ 8%W/W的 表面活性剂以及余量蒸馏水组成, 各组成的含量之和为 100 %。
本发明提供的经皮给药的外用组合物可预防、 治疗皮肤痤疮、 粉刺、 青春痘。
本发明提供的组合物可以保养皮肤, 还可治疗改善皮肤痤疮、 粉刺、 青春痘并具抗氧化作用。 由于不含维生素 A酸, 故不会使肌肤产生光敏感, 在改善皮肤症状的同时, 可避免产生皮肤干燥、 红肿、 发热、 发痒、 皮炎 等副作用, 即使长期使用亦无过量问题产生。
下面藉由具体实施例配合所附的图式详加说明, 更容易了解本发明的 目的、 技术内容、 特点及其功效。 摘 要 本发明提供了一种经皮给药的外用组合物, 该组合物主要由维生素 C、 维生素 B群、 胡萝卜素、 维生素 E与香料、 增稠剂、 表面活性剂所组成, 并可局部使用, 用于保养皮肤, 是治疗痤疮、 粉刺、 青春痘及抗氧化的药 物组合物。
17 附图说明:
图 1为本发明的外用组合物施用于皮肤后所产生皮脂量的差异图,其中 横坐标为时间 (周), 纵坐标为皮脂量 ( g/cm2) 。
具体实施方案
本发明提供了一种经皮给药的外用组合物,其为一种不含维生素 A酸, 并可保养皮肤及治疗改善痤疮 、 粉刺、 青春痘等皮肤征状的组合物。
本发明的外用组合物, 主要由维生素 C、 维生素 B群、 胡萝卜素、 维 生素 E与香料、 增稠剂、 表面活性剂组成。 该组合物成分为人体必须维生 素, 且其主要成分中不含维生素 A酸, 即使长期使用亦无过量问题产生。 维生素在体内需要量少, 功能却极为重要, 人体无法自行合成, 必需依赖 外界的摄取。 其中维生素 C在人体中具有防止产生过氧化脂质、 促进胶原 (collagen)形成、 辅助多种酵素、 延緩细胞老化的功能, 并且能促进血液循 环、 可使黑色素逐渐还原; 因此普遍认为可以帮助皮肤再生, 抑制产生黑 色素以及可增强免疫力。
维生素 B群并非单一而是数种合在一起的维生素, 包括维生素
(thiamin)、维生素 B2(riboflavin)、烟酸 (Niacin)、维生素 B5 (pantothenic acid), 维生素 B6 (pyridoxal),叶酸 (folic acid)、维生素 B12(cobalamin)及生物素 (biotin) 等成份, 主要为辅酶成份, 功能为促进葡萄糖氧化, 脂肪和蛋白质释放能 量, 以维持神经系统的正常功能, 为细胞生长、 再生、 血球生成与合成核 蛋白和髓鞘质 (myelin)所必需, 并能活化叶酸辅助酵素而促进红血球生成。
维生素 E被认为是抗氧化剂, 能抑制血小板的凝集, 防止红血球细胞 膜氧化以免其遭破坏而造成贫血, 在组织内维持细胞膜完整以及促进亚麻 油酸的正常功能, 保护肌肉和神经组织的构造和功能, 以增加末端血管的 血流量, 可有效改善血流情形。 虽然维生素 E具备上述活性, 但是目前上 市品牌中如维生素 E搭配芦荟哇绿 (Wal Green) 的商品,或是含维生素 E的 罗活益 (L'oreal Furtur E)并无记载具有保养皮肤, 或是治疗痤疮、 粉刺、 青 春痘, 以及抗氧化的功能。 本发明组合物的活性实验显示该组合物的所述 比例的主要成分, 具备良好功效。 因此必须强调本发明组合物虽然以维生 素(3、 维生素 B群、 胡萝卜素、 维生素 E与香料、 增稠剂、 表面活性剂所 组成, 然其并非本技术领域常规技术所能推定。
本发明组合物主要成分由维生素 C 1 ~ 45%W/W、 维生素 B群 1 ~ 5%W/W、 胡萝卜素 1 ~ 3%W/W、 维生素 E 2 ~ 90%W/W与香料 0.1 ~ 2% W/W、 增稠剂 1 ~ 5%W/W、 表面活性剂 1 ~ 8%W/W及适量蒸馏水所组成。 且主要成分比例优选为维生素 C 4 ~ 15%W/W、 维生素 B群 1 ~ 3% W/W、 胡萝卜素 1 ~ 2%W/W、 维生素 E 20 ~ 65%W/W。
本发明提供了一种不含维生素 A酸的组合物, 其为可局部给药治疗痤 疮 、 粉刺、 青春痘的组合物。 由于本发明由维生素 C、 维生素 B群、 胡萝 卜素 、 维生素 E与香料、 增稠剂、 表面活性剂所组成, 其可经皮给药施用 于皮肤、颜面等肢体的局部位置, 以达到保养皮肤, 治疗改善痤疮 、粉刺、 青春痘等征状, 以及抗皮肤氧化的功效。
其中 , 该局部给药的组合物必要时可添加各种赋形剂、 载体或稀释剂 , 提供直接涂敷患处的软膏剂型、 乳剂、 洗剂或是贴剂。 该剂型在本领域常 规制剂方法中添加淀粉、 羧曱基纤维素钠等粘合剂, 或以磷酸盐类緩冲液 调整酸碱度使其 pH值达适当程度; 该剂型亦可依常规制剂方法添加渗透 促进剂, 也可选用甘草等天然植物萃取物。
实 施 例 一
处 方 Lo-108
维生素 E 65
维生素 C 4
维生素 B群 -complex 1 胡萝卜素(carotene)
香料 (Flavor)
表面活性剂(Surfactant)
增稠剂 (Thickening agent)
将上述原料维生素 C、 维生素 B群- complex, 溶于少量蒸馏水中, 再 将胡萝卜素 (carotene), 维生素 E、 香料 (Flavor)、 表面活性剂(Surfactant)、 增稠剂 (Thickening agent)混合, 而后混合两溶液并补足蒸馏水量。 实 施 例 二
处 方 Lo-110 维生素 E 20 维生素 C 20
维生素 B群- complex 2
胡萝卜素 (carotene) 2 香料 (Flavor) 2 表面活性剂(Surfactant) 8 增稠剂(Thickening agent) 1 蒸馏水 20 将上述原料维生素(、 维生素 B群- •complex、溶于少量蒸馏水中, 另外 将胡萝卜素 (carotene), 维生素 E、 香料 (Flavor)、 表面活性剂(Surfactant)、 增稠剂相混合, 而后将两溶液相混合并补足蒸馏水量。 实 施 例 三
处 方 Lo-122
維生素 E 85 维生素 C 2
维生素 B群- complex 1
胡萝卜素(carotene) 1
香料 (Flavor) 0·1
表面活性剂(Surfactant) 3
增稠剂(Thickening agent) 2
渗透促进剂 0-5
蒸馏水 15 将上迷原料维生素 C、 维生素 B群- complex、溶于少量蒸媳水中, 另外 将胡萝卜素 (carotene), 维生素 E、 香料 (Flavor)、 表面活性剂(Surfactant)、 增稠剂相混合, 而后将两溶液相混合并补足蒸馏水量。 实 施 例 四
处 方 Lo-130
維生素 E 40 维生素 C 10 维生素 B群 -complex 3 胡萝卜素 (carotene) 2 香料 (Flavor) 2 表面活性剂 ( Surfactant) 10 增稠剂 (Thickening agent) 5 蒸馏水 20 将上述原料维生素(:、 维生素 B群- -complex, 溶于少量蒸馏水中。 另外 将胡萝卜素 (carotene), 维生素 E、 香料 (Flavor)、 表面活性剂(Surfactant)、 增稠剂相混合, 而后将两溶液相混合并补足蒸馏水量。
8 实 施 例 五 处 方 Lo-18
维生素 E 90
维生素 C 1
维生素 B群 -complex 1
胡萝卜素 (carotene) 1
香料 (Flavor) 0.5
表面活性剂(Surfactant) 3
增稠剂(Thickening agent) 3
蒸镏水 qs 将上述原料维生素 C、 维生素 B群- complex、溶于少量蒸馏水中, 另外 将胡萝卜素 (carotene), 维生素 E、 香料 (Flavor)、 表面活性剂(Surfactant)、 增稠剂相混合, 而后将两溶液相混合并补足蒸馏水量。 实 施 例 六
处 方 Lo-27
维生素 E 30
维生素 C 45
维生素 B群 -complex 1
胡萝卜素(carotene) 2
香料 (Flavor) 2
表面活性剂(Surfactant) 8
增稠剂(Thickening agent) 1
渗透促进剂 0.1
蒸馏水 qs
将上述原料维生素 C、 维生素 B群- complex、 溶于少量蒸馏水中, 另 外将胡萝卜素 (carotene), 维生素 E、 香料 (Flavor). 表面活性剂(Surfactant)、 增稠剂相混合, 而后将两溶液相混合并补足蒸馏水量。 实 施 例 七
Lo-22
处 方
维生素 E 80
维生素 C 8
维生素 B群- complex 4
胡萝卜素(carotene) 3 香料 (Flavor)
表面活性剂(Surfactant) 3
增稠剂(Thickening agent) 2 蒸馏水 qs 将上述原料维生素 C、 维生素 B群- complex、溶于少量蒸馏水中, 另外 将胡萝卜素 (carotene), 维生素 E、 香料 (Flavor), 表面活性剂(Surfactant)、 增稠剂相混合, 而后将两溶液相混合并补足蒸馏水量。 实 施 例 八
处 方 Lo-39
维生素 E 30 维生素 c 10 维生素 B群 -complex 5 胡萝卜素 (carotene) 2 香料 (Flavor) 2 表面活性剂(Surfactant) 10 增祸剂 (Thickening agent) 5 渗透促进剂 1.5 蒸馏水 qs
10 将上述原料维生素(、 维生素 B群- complex、溶于少量蒸餾水中, 另外 将胡萝卜素 (carotene), 维生素 E、 香料 (Flavor)、 表面活性剂(Surfactant)' 增稠剂相混合, 而后将两溶液相混合并补足蒸馏水量。 活性实验:
试验一: 痤疮病患使用 Lo-108的疗效评估
材料及方法: 本试验是采用开放式临床效用评估方法, 于 2001年 2月 至 8月半年内选择门诊中的痤疮病患 60名, 男性(30名), 女性(30名) 年龄 17岁〜 42岁, 平均为 25岁。 使用 Lo-108局部敷面治疗共六个月, 每 天敷面 3小时至 8小时(过夜)。 每两周回诊一次记录痤疮数量及性质的改 变, 方法如下:
1.患部先用洗面奶 (皂) 清洗干净后, 待皮肤干燥再敷药。
2.敷药量 2 ml左右, 再以纱布覆盖。
3.敷药三小时以上洗净, 不可擦拭任何保湿乳液(霜)。
4.若有脓包应先行挤去再行敷药。
若病患有脓包配合口服抗生素, 如四环霉素或强力霉素 (Vibramycin)治 疗一星期, 其余时间禁用他种痤疮疗法, 如维生素 A酸(Vitamin A Acid ) 口服或外用, 或荷尔蒙治疗法。
结果由医师及病患本人视其粉刺数目、 丘疹数目、 脓包数目、 红肿程 度而制定严格等级及改善程度百分比进行评估。
表 1 Lo-108的疗效评估
敷药前(个) 敷药 8周后 (个) 粉刺平均数
43.5 20.1 (ρ<0.01)
(mean no. of comedones)
丘疹平均数
21.0 2.1 (p<0.001)
(mean no. of papules)
脓包平均数
8.9 0 (p<0.0001)
(mean no. of pustules)
嚢肿平均数
0.8 0
(mean no. of cysts) 结果如表 1所示, 结果显示: 黑头及白头粉刺于 8周治疗后, 数量有 明显减少, 由平均 43.5个降至平均 20.1个(p<0.01 ), 且毛孔开口缩小的发 红性丘疹数量减少更是有显著性差异, 由平均 21.0个降至 2.1个 (p < 0.001); 脓包及嚢肿的红肿现象的消失, 由平均数 8.9及 0.8降至无, 仅仅 残留部份红斑及凹陷的疤痕。 评估中除了发现 Lo-108具有消炎、 降温和消 肿的能力外, 对于皮肤的过度角质化增生的现象亦有减少趋势, 使皮肤更 为光滑。 凹陷疤痕的改善仅伴有红肿者有些许改善, 这可能是由消肿以后 所得的印象。
以往使用的去角质外用药或抗生素外用药常造成的皮肤干燥脱皮刺 痛, 甚至红肿等副作用, 因 Lo-108兼具保湿效应而未发生。
综合上述数据, 可以认定 Lo-108具有治疗痤疮的疗效, 甚至具有去角 质, 减少皮脂分泌量、 杀菌消炎并有增加角质含水量等作用。 试验二: 皮脂溢出抑制能力的对照评估
20个健康的自愿者参与此项临床试验, 年龄为 18至 55岁之间, 测试 者的额头部位皮肤, 分左右两边, 一边涂抹 Lo-108, —边不涂抹用来加以 对照。 涂抹的方式是每天晚上涂抹约 lml ~ 2 ml的 Lo-108三个小时后, 清 洗干净, 共 4星期, 每星期回诊检测左、 右两额各自的皮脂量, 每次接受 检测的时间为固定时间区间。
皮脂溢出量的测试是用皮脂测量仪 Sebometer 810 PC (Courage and Khazaka Ltd, Germany)测定皮表的油脂量, 由于测定左右两侧皮脂量百分 比差, 许多干扰变量可以减至最低。 皮脂测量的原理是利用器具前的一块 0.1 mm厚, 64 mm2面积的不透明塑料物质, 压在皮肤表面 30秒后, 因为 吸收皮脂而增加透明度, 且与皮脂量成线性的增加, 也就是说皮脂与透明 度相关成正比, 如表 2所示, 经由光度计的测量可经由公式转换成毫克 / 平方厘米。 皮肤的油脂测定
Figure imgf000015_0001
本试验组及对照组由于是同一人额部的左右边皮肤, 因此温度、 湿度 的变化, 受测人的运动程度, 流汗程度等干扰因素均可以排除不计。 利用
ANOVA ( Analysis of variance )的统计方法得到, 测试组的额部油脂明显低 于控制组, 在统计学上有显著性(Pr>F 0.0001 )意义。 请参见附图 1, 可见 每周的平均差异有趋向明显的倾向, 经由 ANOVA统计法, 如下列表 3所 示 Lo-108的皮脂量数据表可见, 施用一周后皮脂量的增减已有统计学上的 显著差异(pr〉F 0.0001 )。 如表 4所示, 也就是使用愈久结果相似, 没有随 时间增加(pr〉F 0.2854 )。 以上的结果显示, Lo-108可以有效去除或抑制油 脂分泌达 12小时以上, 使皮脂腺的开口皮脂量(发生痤疮的主因之一)得 到暂时性的舒緩。 这种效用可以在短期内达成, 每天使用, 可以维持其抑 制皮脂的效用长达四周以上。
皮脂量数据表
Figure imgf000015_0002
注: 以 20个病人左脸颊敷药 Lo-108为处理组, 右脸频擦基剂为对照组。 油脂量差异
Figure imgf000016_0001
注: treat*time为治疗和时间的交互作用。
试验三 灼伤及伤痕复原的动物实验
本实验所用的大白鼠鼠龄为八周大, 雄性大白鼠 (Wistar种;), 平曰飼养 于成功大学动物中心, 该中心为南部唯一合乎国外要求 (SPF)的动物培育单 位。 大鼠饲养在 25士 1 °C的具有空调的动物室中, 所有大白鼠皆可自由进食 及饮水。
灼伤实验:
本项步骤主要参照 Kistler等人的实验方法, 并使用动物自身对照比较 的观察。实验步骤如下:每只大白鼠先以 65mg/kg的戊巴比妥(pentobarbital ) 麻醉, 待其昏睡后, 将背部分成四个固定区域, 每个区域约 4cm2; 利用剃 毛机将各区域内毛剃除干净。 然后, 分别用烧红的铁片(温度约在 80-85°C 左右)放置于背部的四个区域约 10秒,造成大白鼠背部的烫伤。步骤结束后, 取下铁片, 并以双氧水 (37%)作简单的消毒、 清洁伤口。 然后, 再依划分区 域分别给予不同的处理; 除了对照用的区域不给药外, 其余三区域分别给 予维生素 E,产品的基剂以及测试产品,给与量以能均匀涂抹伤口面积为基 准。 涂敷后, 即刻使用紧密包扎法保护伤口, 以确保伤口不受细菌感染。 每天定时换药一次并观察老鼠伤口变化, 每日定期照相存证。 连续七日后, 将动物处死并取四个区域的组织作病理切片, 委托新光医学中心的病理专 家李进成博士帮助评估创面病理学的变化。
14 [结果]
由灼伤的恢复情形来看, 在产品处理的部位, 炎症的变化较为减弱。 结果显示, 对照部位的炎症与产品基剂处理部位没有多大差异。 产品处理 的部位则较无炎症的变化。
伤口复原实验:
本实验使用八周大雄性的大白鼠 (Wistar种), 依照上述的实验步骤, 将 麻醉的大白鼠背部分成四个固定区域, 每个区域约 4cm2, 使用剃毛机将各 区域鼠毛剃除干净。 然后分别用手术刀在背部各区域割开约一公分长, 深 度可看肌肉层的伤痕。 接着, 以双氧水 (37%)消毒并清洁伤口。 同样地, 再 依划分区域分别投与不同的处理, 除了对照区域不给药外, 其余三组区域 分别给予维生素 E产品的基剂以及测试产品, 给与量以能均匀涂抹伤口面 积为基准。 涂敷后, 即刻紧密包扎伤口, 以确保伤口不 ¾细菌感染。 每天 定时换药一次并观察老鼠伤痕的复原情形, 每日定期照相存证。 最后, 依 照复原到正常所需的日数来相互比较; 日数愈少者, 表示复原愈快。
[结果]
由割伤的恢复情形来看, 在产品处理的部位, 复原的时间短; 约 7.13 +1.27天 (N=8)。 对照部位的伤痕 11.00 + 2.24天 (N=8); 与产品基剂处理部 位的 10.13 + 1.62 (N=8) 无显著差异 (Ρ>0·05)。
试验四 抑菌实验
本实验使用三种菌株分别为金葡萄球菌 (Staphylococcus aureus,
Methicillin Restant(ATCC 33591)、 Staphylococcus aureus)、 痤疾菌
(Propionibacterium acnes(ATCC 6919)), 经各自适用的培养基培养后, 以 0.03μ1/πι1、 Ο.ΙμΙ/mK 0.3μ1/ιηΚ ΙμΙ/mK 3μ1/ιηΚ ΙΟμΙ/mK 30μ1/η Κ ΙΟΟμΙ/ml 的 Lo-110分析其抑菌浓度为 100μ1/πι1。
以上描述了本发明优选实施方式, 本领域技术人员可进行并不偏离本 发明范畴和精神的改进和变化。

Claims

权 利 要 求
1、 一种经皮给药的外用组合物, 主要成分包括维生素 C 1~45%W/W、 维生素 B群 1~5%W/W、 胡萝卜素 1~3%W/W、 维生素 E 2〜90%W/W。
2、 如权利要求 1所述的外用组合物, 其主要成分为维生素 C 4〜15% W/W、 维生素 8群 1~3%W/W、 胡萝卜素 1〜2%W/W、 维生素 E 20~65% w/w„
3、 如权利要求 1或 2所述的外用组合物, 其组成还包括香料 0.1〜2% W/W、 增稠剂卜 5%W/W、 表面活性剂 1~8% W/W及适量蒸馏水。
4、如权利要求 1所述的外用组合物,该组合物应用于皮肤的局部位置。
5、 一种经皮给药的外用组合物, 所述组合物用于制备对痤疮、 粉刺、 青春痘具有治疗作用的药物, 所述组合物主要成分为维生素 C
1〜45%W/W、 维生素 B群 1~5%W/W、 胡萝卜素 1〜3%W/W、 维生素 E 2~90%W/W与香料 0.卜 2% W/W、 增稠剂 1~5%W/W、 表面活性剂
1~8%W/W以及适量蒸馏水。
6、 一种经皮给药的外用组合物, 所述组合物应用于保养皮肤, 其主要 成分为维生素 C 1〜45%W/W、 维生素 B群 1〜5%W/W、 胡萝卜素
1~3%W/W、维生素 E 2~90%W/W与香料 0.1~2%W/W、增稠剂 1~5%W/W、 表面活性剂 1〜8% W/W及适量蒸馏水。
7、 一种经皮给药的外用组合物, 所述组合物具有抗氧化作用, 主要 成分为维生素 C 1〜45%W/W、 维生素 B 群 1~5%W/W、 胡萝卜素 1~3%W/W、维生素 E 2~90%W/W与香料 0.1~2%W/W、增稠剂 1~5% W/W、 表面活性剂 1~8% W/W及适量蒸馏水。
8、 如权利要求 1 所述的外用组合物在治疗痤疮、 粉刺、 青春痘方面 的应用。
16
PCT/CN2003/000358 2003-05-16 2003-05-16 Composition a usage externe administree par voie percutanee WO2004100923A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020057021808A KR100673044B1 (ko) 2003-05-16 2003-05-16 경피 투여용 국소 조성물
BRPI0318343-2A BR0318343A (pt) 2003-05-16 2003-05-16 composição tópica para administração transdérmica
EP03727132A EP1625844A4 (en) 2003-05-16 2003-05-16 COMPOSITION FOR EXTERNAL USE PERCUTANEOUSLY ADMINISTERED
CA002525465A CA2525465A1 (en) 2003-05-16 2003-05-16 Topical composition for transdermal administration
PCT/CN2003/000358 WO2004100923A1 (fr) 2003-05-16 2003-05-16 Composition a usage externe administree par voie percutanee
JP2004571754A JP2006525945A (ja) 2003-05-16 2003-05-16 皮膚を通して投薬される外用組成物
AU2003234980A AU2003234980B2 (en) 2003-05-16 The composition for external use by percutaneous administration
US10/811,420 US7655255B2 (en) 2003-05-16 2004-03-26 Topical composition for transdermal administration
US11/446,051 US20060222689A1 (en) 2003-05-16 2006-06-02 Skin care compositions and methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2003/000358 WO2004100923A1 (fr) 2003-05-16 2003-05-16 Composition a usage externe administree par voie percutanee

Publications (1)

Publication Number Publication Date
WO2004100923A1 true WO2004100923A1 (fr) 2004-11-25

Family

ID=33426287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2003/000358 WO2004100923A1 (fr) 2003-05-16 2003-05-16 Composition a usage externe administree par voie percutanee

Country Status (7)

Country Link
US (1) US7655255B2 (zh)
EP (1) EP1625844A4 (zh)
JP (1) JP2006525945A (zh)
KR (1) KR100673044B1 (zh)
BR (1) BR0318343A (zh)
CA (1) CA2525465A1 (zh)
WO (1) WO2004100923A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1752132A3 (en) * 2005-08-08 2010-01-13 Lotus Pharmaceutical Co., Ltd. Skin cosmetic compositions

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
CN1250229C (zh) * 2003-05-16 2006-04-12 美时化学制药股份有限公司 经皮给药的外用组合物
FR2866563B1 (fr) * 2004-02-19 2008-01-11 Oreal Composition de peeling comprenant de l'acide 8-hexadecene- 1,16 dicarboxylique
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2005102282A1 (en) * 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US7550488B2 (en) * 2005-12-30 2009-06-23 Dr. N's Health Care Products Llc Application methods to rapidly alter disease and injury states using molecular transport of B6
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP3045171A1 (en) 2009-06-24 2016-07-20 Strategic Science & Technologies, LLC Topical composition
EP2445493A1 (en) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topical composition containing naproxen
WO2012092523A1 (en) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
CN103429247A (zh) 2010-12-29 2013-12-04 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
JP6274714B2 (ja) * 2011-07-29 2018-02-07 株式会社ダイセル 皮脂産生抑制剤
JP2014144929A (ja) * 2013-01-29 2014-08-14 Daiichi Sankyo Healthcare Co Ltd ビタミン類を含有するニキビの予防又は治療用組成物
JP2015166330A (ja) * 2014-03-04 2015-09-24 株式会社マンダム 化粧料
CN108371669A (zh) * 2018-04-18 2018-08-07 董新声 一种用于青春痘的外用药

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938960A (en) * 1984-03-07 1990-07-03 Roshdy Ismail Agents for the treatment and protection of the skin
US5710177A (en) * 1992-12-18 1998-01-20 Beiersdorf Ag Synergistic combinations of active substance for the cosmetic or dermatological care of the skin, hair & nails
CN1236634A (zh) * 1998-05-22 1999-12-01 李华 多功能痤疮药液及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2240187A1 (de) * 1972-08-16 1974-02-21 Jereb Franz Dr Albin Salbe
DE3504695A1 (de) * 1985-02-12 1986-08-14 Roshdy Dipl.-Chem. Dr. 5000 Köln Ismail Haarwuchsmittel
LU87145A1 (fr) * 1988-02-26 1989-09-20 Oreal Methode pour ameliorer l'aspect esthetique de la peau a l'aide de melanges polyvitaminiques
US5602183A (en) 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5646190A (en) * 1991-03-01 1997-07-08 Warner-Lambert Company Acne treating-wound healing compositions and methods for preparing and using same
FR2681784B1 (fr) 1991-10-01 1995-06-09 Fabre Pierre Cosmetique Composition dermatologique et/ou cosmetologique contenant des retinouides et utilisation de nouveaux retinouides.
DE4328871A1 (de) * 1993-08-27 1995-03-02 Beiersdorf Ag Mittel gegen empfindliche, hyperreaktive Hautzustände, atopische Dermatiden, Pruritus, Psoriasis Prurigo, Photodermatosen und Ichthyosis
AU7787194A (en) * 1993-09-23 1995-04-10 Ali Altunkaya Composition containing omega 3 and/or omega 6 polyunsaturated acids having from 12 to 22 carbon atoms
JPH09291011A (ja) * 1996-04-24 1997-11-11 Kose Corp 外用に適する組成物
US5804594A (en) 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US6036946A (en) * 1997-12-24 2000-03-14 Shaklee Corporation Methods for protecting skin from damaging effects of ultraviolet light
JP4150501B2 (ja) * 1997-12-24 2008-09-17 シャクリー コーポレイション 紫外光の傷害作用からの高効率皮膚保護を備える組成物
US6217852B1 (en) * 1998-08-15 2001-04-17 Skinnovative Dermatologic Concepts, L.L.C. Personal cleansing compositions having photoprotective agents
US6630163B1 (en) * 1999-04-22 2003-10-07 Howard Murad Method of treating dermatological disorders with fruit extracts

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938960A (en) * 1984-03-07 1990-07-03 Roshdy Ismail Agents for the treatment and protection of the skin
US5710177A (en) * 1992-12-18 1998-01-20 Beiersdorf Ag Synergistic combinations of active substance for the cosmetic or dermatological care of the skin, hair & nails
CN1236634A (zh) * 1998-05-22 1999-12-01 李华 多功能痤疮药液及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1625844A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1752132A3 (en) * 2005-08-08 2010-01-13 Lotus Pharmaceutical Co., Ltd. Skin cosmetic compositions

Also Published As

Publication number Publication date
BR0318343A (pt) 2006-07-11
CA2525465A1 (en) 2004-11-25
US7655255B2 (en) 2010-02-02
JP2006525945A (ja) 2006-11-16
KR100673044B1 (ko) 2007-01-22
EP1625844A4 (en) 2009-05-13
EP1625844A1 (en) 2006-02-15
AU2003234980A1 (en) 2004-12-03
KR20060019540A (ko) 2006-03-03
US20040228908A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
JP6495183B2 (ja) 表面の創傷を処置するための組成物および方法
JP4745608B2 (ja) 電子伝達剤のリン酸誘導体を用いた皮膚治療
AU2020201781B2 (en) Composition, system and method for treating skin
WO2004100923A1 (fr) Composition a usage externe administree par voie percutanee
US20060222689A1 (en) Skin care compositions and methods
JP2011088930A (ja) 二酸化炭素経皮・経粘膜吸収用組成物
US11696907B2 (en) Wound healing composition
JP2013163681A (ja) 二酸化炭素経皮・経粘膜吸収用組成物
EP1752132A2 (en) Skin cosmetic compositions
JP5699184B2 (ja) 二酸化炭素経皮・経粘膜吸収用組成物
RU2325900C2 (ru) Состав для кожи наружного применения
AU2006202906A1 (en) Compositions for use with skin
WO2011123619A2 (en) Permeable mixtures, methods and compositions for the skin
TWI325324B (zh)
JP2013177461A (ja) 二酸化炭素経皮・経粘膜吸収用組成物
KR20190132197A (ko) 여드름이 생기기 쉬운 피부의 치료 및 예방에 사용하기 위한 화장품 조성물
JP2013166779A (ja) 二酸化炭素経皮・経粘膜吸収用組成物
ZA200509183B (en) Topical composition for transdermal administration

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200501649

Country of ref document: VN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003727132

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12005501990

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2525465

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005/09183

Country of ref document: ZA

Ref document number: 200509183

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004571754

Country of ref document: JP

Ref document number: 1020057021808

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2579/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005135164

Country of ref document: RU

Ref document number: 2003234980

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2003727132

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057021808

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0318343

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2003234980

Country of ref document: AU